Hydromorphone
Management of pain severe enough to require an opioid analgesic and for which alternate...
Boxed warning
- WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION Addiction, Abuse, and Misuse Hydromorphone Hydrochloride Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ]. Life-Threatening Respiratory Depression Serious, ... (see full label)
High-alert medication
- Opioids, all routes (class)
Indications
- Management of pain severe enough to require an opioid analgesic and for which alternate...
Adult dosing
- initial im sc: dose: 1; unit: mg; route: IM/SC; interval: 1 to 2 mg every 2 to 3 hours; fixed: true; labelExcerpt: Intramuscular or Subcutaneous Use : The usual starting dose is 1 mg to 2 mg every 2 to 3 hours as necessary. ( 2.2 )
- initial iv: dose: 0.2; unit: mg; route: IV; interval: 0.2 to 1 mg every 2 to 3 hours; fixed: true; titrationTarget: Titrate to effect. Individually titrate to a dose that provides adequate analgesia and minimizes adverse reactions; labelExcerpt: Intravenous Use : The usual starting dose is 0.2 mg to 1 mg every 2 to 3 hours. The injection should be given slowly , over at least 2 to 3 minutes. ( 2.2 )
Pediatric dosing
- Consult pharmacy/current label
Renal adjustment
- Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of renal impairment. Label: "Renal Impairment: Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of renal impairment. ( 2.4 )"
Hepatic adjustment
- Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of hepatic impairment.
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma
- Known or suspected gastrointestinal obstruction
- Hypersensitivity to hydromorphone or sulfites
Clinical pearls
- Greatest risk of respiratory depression during initiation or dosage increase.
- Give IV injections slowly over at least 2-3 minutes.
- Assess patient risk for addiction/abuse/misuse prior to prescribing and monitor regularly.
- Do not abruptly discontinue in physically dependent patients; taper by 25-50% every 2-4 days.
Source and review
- DailyMed label (hydromorphone hydrochloride), Set ID 67e79859-4efc-4ea7-8211-cadf746bc864, effective 2026-07-30. Last reviewed: 2026-11-11
RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties